Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
McKesson
Chubb
Mallinckrodt
McKinsey
Fuji
QuintilesIMS
UBS
Covington

Generated: April 26, 2018

DrugPatentWatch Database Preview

VELBAN Drug Profile

« Back to Dashboard

Which patents cover Velban, and what generic alternatives are available?

Velban is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in VELBAN is vinblastine sulfate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vinblastine sulfate profile page.
Drug patent expirations by year for VELBAN
Medical Subject Heading (MeSH) Categories for VELBAN
Synonyms for VELBAN
1217677-42-3
143-67-9
29060 LE
AB48729
AC1L68CZ
AI3-52943
AKOS024456494
Ambap143-67-9
AN-15534
AS-12480
Belvan, VLB
BT001134
C11626
C46H58N4O9.H2O4S
C46H58N4O9.H2SO4
C46H60N4O13S
CCRIS 2584
CHEBI:9984
CHEMBL376464
D01068
DR003630
EINECS 205-606-0
EXAL
Exal (TN)
FT-0603354
KDQAABAKXDWYSZ-JKDPCDLQSA-N
l)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate
LS-162171
methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-met
MFCD00082457
MolPort-006-111-039
MolPort-039-052-360
NSC 49842
NSC-49842
NSC49842
Rozevin sulfate
SCHEMBL3550
Velban (TN)
Velban (TN) (Lilly)
Vinblastine 5
Vinblastine sulfate
Vinblastine sulfate (JP17/USP)
Vinblastine sulfate [USAN:JAN]
Vinblastine Sulfate Hydrate
Vinblastine sulphate
Vinblastine, hydrate
Vincaleucoblastine sulfate
VINCALEUKBLASTINE SULFATE
Vincaleukoblastine sulfate
Vincaleukoblastine sulfate (1:1) (salt)
Vincaleukoblastine sulfate salt
Vincaleukoblastine, hydrate
Vincaleukoblastine, monohydrate
Vincaleukoblastine, sulfate
Vincaleukoblastine, sulfate (1:1) (salt)
Vinolastine sulfate
VLB
VLB monosulfate
VLB SULFATE SALT
WLN: T C6 B5665/BS 2AB S BX IN QN NU & & TTTJ FO1 I1 KVO1 KQ LOV1 M2 E-CT F6 D596A EN ON & & TTJ CVO1 Q
WLN: T C6 B5665/BS 2AB S BX IN QN NU & & TTTJ FO1 I1 KVO1 KQ LOV1 M2 E-CT F6D596A EN ON & & TTJ CVO1 Q
Z2241984238

US Patents and Regulatory Information for VELBAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly VELBAN vinblastine sulfate INJECTABLE;INJECTION 012665-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKesson
Julphar
Citi
QuintilesIMS
Teva
AstraZeneca
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.